tiprankstipranks
Blurbs

Analysts’ Top Healthcare Picks: Vir Biotechnology (VIR), Blueprint Medicines (BPMC)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vir Biotechnology (VIRResearch Report), Blueprint Medicines (BPMCResearch Report) and Caribou Biosciences (CRBUResearch Report) with bullish sentiments.

Vir Biotechnology (VIR)

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Vir Biotechnology, with a price target of $200.00. The company’s shares closed last Monday at $40.48, close to its 52-week low of $25.31.

According to TipRanks.com, Trucchio is ranked 0 out of 5 stars with an average return of -5.4% and a 32.3% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Milestone Pharmaceuticals, and Precision BioSciences.

Vir Biotechnology has an analyst consensus of Moderate Buy, with a price target consensus of $81.83, implying a 109.0% upside from current levels. In a report issued on November 17, Needham also reiterated a Buy rating on the stock with a $80.00 price target.

See the top stocks recommended by analysts >>

Blueprint Medicines (BPMC)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Blueprint Medicines, with a price target of $135.00. The company’s shares closed last Monday at $98.28.

According to TipRanks.com, Fein is a 4-star analyst with an average return of 10.5% and a 41.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Deciphera Pharmaceuticals, and Global Blood Therapeutics.

Blueprint Medicines has an analyst consensus of Moderate Buy, with a price target consensus of $124.63, a 21.6% upside from current levels. In a report released yesterday, Wedbush also maintained a Buy rating on the stock with a $139.00 price target.

Caribou Biosciences (CRBU)

In a report released today, Robert Burns from H.C. Wainwright initiated coverage with a Buy rating on Caribou Biosciences and a price target of $28.00. The company’s shares closed last Monday at $17.05, close to its 52-week low of $15.00.

According to TipRanks.com, Burns ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -11.2% and a 24.1% success rate. Burns covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Black Diamond Therapeutics, and Atara Biotherapeutics.

Currently, the analyst consensus on Caribou Biosciences is a Strong Buy with an average price target of $29.00, representing a 60.2% upside. In a report issued on November 15, Citigroup also upgraded the stock to Buy with a $27.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on VIR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed